| Description | MM 11253 is a RARγ antagonist with IC50 of 44nM. |
| In vitro | MM11253 blocks the ability of MM11254 and MM11389 to inhibit squamous cell carcinoma cell growth [2]. |
| Target activity | RARβ:>1000 nM (IC50), RARγ:44 nM (IC50), RXRα:>1000 nM (IC50), RARα:1000 nM (IC50) |
| Synonyms | MM-11253 |
| molecular weight | 462.67 |
| Molecular formula | C28H30O2S2 |
| CAS | 345952-44-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 100 mg/mL (216.1 mM), Sonication is recommended. |
| References | 1. M I Dawson, et al. Retinoic acid (RA) receptor transcriptional activation correlates with inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase (ODC) activity by retinoids: a potential role for trans-RA-induced ZBP-89 in ODC inhibition. Int J Cancer. 2001 Jan 1;91(1):8-21. 2. Q Le, et al. Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids. Oncogene. 2000 Mar 9;19(11):1457-65. |